Abstracts Archive - Page 1693 of 2425 - ACR Meeting Abstracts

Abstract Number: 48 • 2015 ACR/ARHP Annual Meeting
Polypharmacy Is a Predictor of Hospitalisation in Patients with Rheumatoid Arthritis
Maria Filkova¹, Joao Carvalho¹, Sam Norton², David L. Scott¹, Tim Mant³, Andrew P. Cope¹, Mariam Molokhia⁴ and James Galloway¹, ¹Academic Department of Rheumatology, King´s College London, London, United Kingdom, ²Department of Psychological Medicine, King´s College London, London, United Kingdom, ³Quintiles Drug Research Unit at Guy's Hospital, London, London, United Kingdom, ⁴Division of Health and Social Care Research, King´s College London, London, United Kingdom
Background/Purpose: Multimorbidity is a major problem in rheumatoid arthritis (RA) but is difficult to measure. Polypharmacy (PP) - co-prescribing an individual multiple medications – is…
Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting
Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld² and Mona Trivedi³, ¹Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Rheumatology, Amgen, Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…
Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Kathleen Andersen¹, Daming Lin², Susan J. Bartlett^3,4, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰, Diane Tin¹¹, J Carter Thorne¹², VP Bykerk^13,14 and CATCH Investigators, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…
Abstract Number: 51 • 2015 ACR/ARHP Annual Meeting
Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study
Daniel B. Horton^1,2,3, Kevin Haynes^1,4, Michelle R. Denburg^1,5, Mihir Thacker⁶, Carlos D. Rose², Mary E. Putt¹, Mary B. Leonard⁷ and Brian L. Strom^1,3, ¹Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁴Clinical Epidemiology, HealthCore, Wilmington, DE, ⁵Pediatrics, Children’s Hospital of Philadelphia, Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Orthopedics, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, ⁷Pediatrics, Division of Nephrology, Stanford School of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Glucocorticoids have long been linked to the development of osteonecrosis, mostly in heavily exposed patients from specialty clinics. We tested the hypothesis that oral…
Abstract Number: 52 • 2015 ACR/ARHP Annual Meeting
Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian As Patients
Nagma Bansal¹, Lalit Duggal², Neeraj Jain², Amit Dua³ and Appu Patil¹, ¹Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, DNB trainee, New Delhi, India, ²Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, Consultant, New Delhi, India, ³Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, Fellow, New Delhi, India
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is a complex score for monitoring disease activity and ASDAS calculator is required for estimation. This study aimed…
Abstract Number: 53 • 2015 ACR/ARHP Annual Meeting
Associations Between Race and Income Disparity on Morbidity in Juvenile Dermatomyositis
Kathryn Phillippi¹, Mark Hoeltzel², Angela Byun Robinson^3,4, Susan Kim⁵ and CARRA investigators, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Rheumatology Division, University of Michigan Mott Children's Hospital, Ann Arbor, MI, ³Pediatrics, Rainbow Babies & Children's Hospital / Case Medical Center, Cleveland, OH, ⁴Pediatric Rheumatology, Rainbow Babies and Childrens Hospital, Cleveland, OH, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Disclosure: T32 grant: the National Institutes of Health under Ruth L. Kirschstein National Research Service Award T32 AR007505 from the NIH NIAMS. The CARRA Registry is…
Abstract Number: 54 • 2015 ACR/ARHP Annual Meeting
Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study
Il Woong Sohn¹, Young Bin Joo¹, Soyoung Won², Seung Taek Song¹, Seung Lee³, Hye-Jin Jeong³ and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects frequently in their 20s and 30s. However, SLE could develop in other age group…
Abstract Number: 55 • 2015 ACR/ARHP Annual Meeting
Increased Incidence of Tuberculosis Among Systemic Lupus Erythematous Patients – Should Tuberculosis Screening at Diagnosis be the Next Step?
Ana Maria Gherghe¹, Alexandru Matei², Hermina Gyorfi², Alina Soare¹, Rucsandra Dobrota¹, Mariana Sasu¹, Liviu Macovei², Ioan Ancuta¹, Mihaela Milicescu¹, Mihai Bojinca¹, Victor Stoica² and Carina Mihai¹, ¹Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) represents a major global health problem, responsible for ill health among millions of people each year (1). TB has a higher incidence…
Abstract Number: 56 • 2015 ACR/ARHP Annual Meeting
Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)
Kathryn Jackson, Theresa Walunas, Anh Chung and Rosalind Ramsey-Goldman, Northwestern University, Chicago, IL
Background/Purpose: Care fragmentation is associated with poor health outcomes and is hard to assess in a single-site data registry. The Chicago HealthLNK Data Repository (CHDR)…
Abstract Number: 57 • 2015 ACR/ARHP Annual Meeting
Age, Gender, Racial and Comorbidity Differences Among Systemic Lupus Erythematosus Patients Hospitalized with Ischemic Stroke Compared to the General Population: A Nationwide Analysis
Tapan Mehta¹, Khushboo Sheth², Ronak Soni³, Vishad Sheth⁴, Kathan Mehta⁵ and Christopher Scola⁶, ¹Neurology, University of Connecticut, Farmington, CT, Farmington, CT, ²Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ³Central Michigan University, Mount Pleasant, MI, ⁴Mercy Catholic Medical Center, Yeadon, PA, ⁵Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, Pittsburgh, PA, ⁶Rheumatology, Hartford Hospital, Hartford, CT
Background/Purpose: To determine if age, gender and racial discrepancies exist, and to determine the occurence of comorbidities among patients hospitalized with ischemic stroke with Systemic…
Abstract Number: 58 • 2015 ACR/ARHP Annual Meeting
Attribution of Cause of End-Stage Renal Disease Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Cristina Drenkard¹, Stephen Pastan² and S. Sam Lim³, ¹Department of Medicine, Emory University, Atlanta, GA, ²Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: The attributed cause of end-stage renal disease (ESRD) in the United States Renal Data System (USRDS) is often used to identify systemic lupus erythematosus…
Abstract Number: 59 • 2015 ACR/ARHP Annual Meeting
Variation in Heart Failure Hospitalizations Among U.S. Medicaid Recipients with SLE 2000-2010, By Race and Ethnicity
Medha Barbhaiya¹, Candace H. Feldman¹, Hongshu Guan¹, Jose A. Gomez Puerta², Michael A. Fischer³ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Heart failure (HF) is a leading cause of hospital admissions. In the US, Blacks have higher HF prevalence than other racial/ethnic groups. Cardiovascular disease…
Abstract Number: 60 • 2015 ACR/ARHP Annual Meeting
Mortality of Systemic Lupus Erythematosus in Puerto Rico Assessed By Multiple-Cause-of-Death Analysis
Mariangelí Arroyo-Ávila¹, José G. Conde² and Luis M. Vilá¹, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²School of Medicine and Research Centers in Minority Institutions Program, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that is associated with a high morbidity and mortality. The specific causes of death vary…
Abstract Number: 61 • 2015 ACR/ARHP Annual Meeting
Predictors of Mortality Among Patients with Sarcoidosis: A Population-Based Study
Patompong Ungprasert¹, Eva M. Carmona Porquera², James P. Utz², Jay H. Ryu³, Cynthia S. Crowson⁴ and Eric L. Matteson⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ³Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The epidemiology and natural history of sarcoidosis is not well-characterized as only coding-based studies without detailed clinical information from individual medical record review have…
Abstract Number: 62 • 2015 ACR/ARHP Annual Meeting
Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Marco Matucci-Cerinic⁴, Janet E. Pope⁵, Barbara Hinzmann⁶, Siobhan Briody⁷, Janethe de Oliveira Pena⁸ and Oliver Distler⁹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Immunogenetics, Cochin Institute, Paris, France, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁵University of Western Ontario, London, ON, Canada, ⁶Bayer Pharma AG, Berlin, Germany, ⁷Blueprint Partnership, Manchester, United Kingdom, ⁸Bayer HealthCare Pharma, Whippany, NJ, ⁹Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Diffuse cutaneous SSc (dcSSc) is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians traditionally…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].